Epoxides related to dioncoquinone B: Synthesis, activity against multiple myeloma cells, and search for the target protein

被引:4
|
作者
Cheng, Xia [1 ]
Zhang, Guoliang [1 ]
Seupel, Raina [1 ]
Feineis, Doris [1 ]
Bruennert, Daniela [2 ]
Chatterjee, Manik [2 ]
Schlosser, Andreas [3 ]
Bringmann, Gerhard [1 ]
机构
[1] Univ Wurzburg, Inst Organ Chem, D-97074 Wurzburg, Germany
[2] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Translat Oncol, Versbacher Str 5, D-97078 Wurzburg, Germany
[3] Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Josef Schneider Str 2, D-97078 Wurzburg, Germany
关键词
Epoxides; Naphthoquinones; Multiple myeloma; Target identification; Biotinylation; ACETOGENIC ISOQUINOLINE ALKALOIDS; TRIPHYOPHYLLUM-PELTATUM; NAPHTHYLISOQUINOLINE ALKALOIDS; CLICK CHEMISTRY; ENDOPLASMIC-RETICULUM; IDENTIFICATION; DIONCOPHYLLACEAE; EXTRACTION; STRATEGIES; CULTURES;
D O I
10.1016/j.tet.2018.04.056
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
Epoxide 2b is an analog of the synthetic intermediate 2a en route to the polyketide-derived antitumoral naphthoquinone dioncoquinone B (1), isolated from cell cultures of the tropical liana Triphyophyllum peltatum (Dioncophyllaceae). Compound 2b was found to induce strong apoptosis in multiple myeloma cells at a concentration (EC50 = 3.5 mu M), distinctly lower than that of 1 and any related analog, without exerting significant toxicity against normal blood cells. Preliminary studies showed that 2b follows different SAR rules as compared to the naphthoquinones. Among the series of synthesized epoxides, 2b was the most active one and was thus, after biotinylation, subjected to mass spectrometry-based affinity capture experiments aiming at the identification of target proteins. The MS data revealed 2b to address proteins that are associated with stress regulation processes which are critical for multiple myeloma cell survival. (C) 2018 Elsevier Ltd. All rights reserved.
引用
下载
收藏
页码:5102 / 5112
页数:11
相关论文
共 50 条
  • [1] Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma
    Ortiz-Ruiz, Alejandra
    Ruiz-Heredia, Yanira
    Luz Morales, Maria
    Aguilar-Garrido, Pedro
    Garcia-Ortiz, Almudena
    Valeri, Antonio
    Barcena, Carmen
    Garcia-Martin, Rosa Maria
    Garrido, Vanesa
    Moreno, Laura
    Gimenez, Alicia
    Angel Navarro-Aguadero, Miguel
    Velasco-Estevez, Maria
    Lospitao, Eva
    Cedena, Maria Teresa
    Barrio, Santiago
    Martinez-Lopez, Joaquin
    Linares, Maria
    Gallardo, Miguel
    CANCERS, 2021, 13 (07)
  • [2] Molecular mechanisms underlying antitumor activity of camel whey protein against multiple myeloma cells
    Badr, Gamal
    Sayed, Eman Abdo.
    Abdel-Ghaffar, Wafaa H.
    Badr, Badr M.
    Sayed, Leila H.
    Sayed, Aml
    Mahmoud, Mohamed H.
    Alamery, Salman
    SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2021, 28 (04) : 2374 - 2380
  • [3] Droserone and dioncoquinone B, and related naphthoquinones as potent antiausterity agents against human PANC-1 pancreatic cancer cells
    Maneenet, Juthamart
    Tajuddeen, Nasir
    Nguyen, Hung Hong
    Fujii, Rintaro
    Lombe, Blaise Kimbadi
    Feineis, Doris
    Awale, Suresh
    Bringmann, Gerhard
    RESULTS IN CHEMISTRY, 2024, 7
  • [4] Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells
    Klippel, Steffen
    Jakubikova, Jana
    Delmore, Jake
    Ooi, Melissa
    McMillin, Douglas
    Kastritis, Efstathios
    Laubach, Jacob
    Richardson, Paul G.
    Anderson, Kenneth C.
    Mitsiades, Constantine S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (03) : 340 - 351
  • [5] In vitro activity of S-thalidomide against multiple myeloma cells:: A gene and protein expression profile.
    Malpas, J
    Chaplin, T
    Sanmugathasan, A
    Liu, W
    BRITISH JOURNAL OF CANCER, 2003, 88 : S46 - S46
  • [6] Smenamide A Analogues. Synthesis and Biological Activity on Multiple Myeloma Cells
    Caso, Alessia
    Laurenzana, Ilaria
    Lamorte, Daniela
    Trino, Stefania
    Esposito, Germana
    Piccialli, Vincenzo
    Costantino, Valeria
    MARINE DRUGS, 2018, 16 (06):
  • [7] Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells
    Tassone, P
    Goldmacher, VS
    Neri, P
    Gozzini, A
    Shammas, MA
    Whiteman, KR
    Hylander-Gans, LL
    Carrasco, DR
    Hideshima, T
    Shringarpure, R
    Shi, JL
    Allam, CK
    Wijdenes, J
    Venuta, S
    Munshi, NC
    Anderson, KC
    BLOOD, 2004, 104 (12) : 3688 - 3696
  • [8] Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells
    Qu, Bingxue
    Xu, Yongjin
    Lu, Yang
    Zhuang, Weihao
    Jin, Xinxin
    Shi, Qiuqiu
    Yan, Shike
    Guo, Yu
    Shen, Zheyuan
    Che, Jinxin
    Wu, Yize
    Tong, Lexian
    Dong, Xiaowu
    Yang, Haiyan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 235
  • [9] Chimeric antigen receptor-modified T cells against several target antigens in multiple myeloma
    Chang, Lung-Ji
    Liu, Yuchen
    Kuo, Hao-Hsiang
    Tsao, Shih-Ting
    Moreb, Jan S.
    CANCER RESEARCH, 2015, 75
  • [10] Bortezomib-resistant nuclear Factor-κB activity in multiple myeloma cells
    Markovina, Stephanie
    Callander, Natalie S.
    O'Connor, Shelby L.
    Kirn, Jihoon
    Werndli, Jae E.
    Raschko, Martha
    Leith, Catherine P.
    Kahl, Brad S.
    Kim, KyungMann
    Miyamoto, Shigeki
    MOLECULAR CANCER RESEARCH, 2008, 6 (08) : 1356 - 1364